Table 3.
Characteristics of qualifying migraine.
| Treatment group |
|||||
|---|---|---|---|---|---|
| ADAM zolmitriptan |
|||||
| n (%) | Placeboa n = 77 | 1 mg n = 79 | 1.9 mg n = 83 | 3.8 mg n = 82 | Total n = 321 |
| Severity of pain | |||||
| Moderate | 44 (57.1) | 37 (46.8) | 33 (39.8) | 43 (52.4) | 157 (48.9) |
| Severe | 33 (42.9) | 42 (53.2) | 50 (60.2) | 39 (47.6) | 164 (51.1) |
| Nausea present | 51 (66.2) | 56 (70.9) | 60 (72.3) | 59 (72.0) | 226 (70.4) |
| Vomiting present | 6 (7.8) | 3 (3.8) | 7 (8.4) | 5 (6.1) | 21 (6.5) |
| Photophobia present | 75 (97.4) | 73 (92.4) | 77 (92.8) | 78 (95.1) | 303 (94.4) |
| Phonophobia present | 72 (93.5) | 70 (88.6) | 75 (90.4) | 71 (86.6) | 288 (89.7) |
| Aura present | 23 (29.9) | 26 (32.9) | 35 (42.2) | 35 (42.7) | 119 (37.1) |
| Woke up with headache | 44 (57.1) | 41 (51.9) | 43 (51.8) | 36 (43.9) | 164 (51.1) |
a
Consisted of pooled 1-patch and 2-patch placebo groups.